DeSci vs. TradSci: 5 Key Differences Changing Scientific Discovery (R&D Funding And IP Are Getting Rewired)

By Anik Hassan

Global R&D spending topped more than USD 2.75 trillion in 2023, underscoring how capital-intensive science has become as the United States and China together led the league tables, according to WIPO estimates drawing on UNESCO, OECD, and Eurostat sources. Yet success rates for winning NIH research project grants slipped to 19 percent in 2024, which means more proposals are chasing fewer awards, and time to impact keeps stretching for many labs and startups that sit in the valley between promising results and market proof points.

Here’s the thing, the debate now is whether decentralized science, or DeSci, can meaningfully change the incentives around funding, publishing, data sharing, and IP, or whether it is just another tech wrapper on old problems that still burn time and cash for scientists, investors, and patients who need reproducible results and open access to knowledge at a fair price.

This matters to founders who cannot afford multi-year grant cycles, to investors who want earlier signals and liquid exposure to IP, and to researchers who must navigate paywalls like Nature’s €9,500 gold OA option while defending against a documented reproducibility crisis across STEM.

After peaking on its own hype cycle, DeSci is evolving into a practical toolkit that blends blockchain rails, tokenized IP, and community funding to route capital faster to neglected problems and to harden the provenance of data and methods so reproducibility and access improve in small but compounding steps.

Projects like VitaDAO and Molecule are testing whether IP tokens, on-chain governance, and milestone-based treasuries can finance translational research that traditional endowments or grants undervalue, while keeping the scientific record more transparent and auditable from day one, not just at publication. This smells like a real experiment rather than marketing, although sources say the sample size is still small.

Key Data

• Global R&D in real terms reached more than USD 2.75 trillion in 2023, with the United States and China leading worldwide spend, per WIPO estimates using UNESCO, OECD, and Eurostat data.

• NIH R01 equivalent and research project grant success rates declined to 19 percent in 2024, down from 21 percent in 2023, indicating tougher competition for public research funding.

• Authors can pay up to €9,500 to publish gold open access in Nature titles, highlighting persistent cost barriers in elite publishing even as OA expands.

• More than 70 percent of scientists reported failing to reproduce another scientist’s experiments in Nature’s widely cited survey, a signal problem TradSci still struggles to fix at scale.

High top-line R&D spend, lower public grant hit rates, premium OA fees, and reproducibility gaps reveal a system that creates world-class outputs and also leaves many ideas stranded between preprint and product, where funding dries up and verification gets expensive. DeSci attempts to compress this gap by swapping part of the administrative and gatekeeping stack for programmable funding rails, auditable IP packaging, and community governance that can align capital and contributors earlier and more transparently. VitaDAO’s longevity portfolio and Molecule’s IP-NFT model are the most visible testbeds, connecting donors, patients, researchers, and token holders around specific assets and milestones rather than journal prestige alone.

Desci vs. Tradsci: 5 Key Differences

1. Funding and Incentives

TradSci funding funnels through government agencies and philanthropic endowments that emphasize peer review and long cycles, which can slow translational work and penalize novel or interdisciplinary proposals amid falling success rates like NIH’s 2024 outcome of 19 percent on R01 equivalents.

DeSci reframes the capital stack by using DAO treasuries, quadratic funding, and tokenized assets to back projects earlier, with VitaDAO providing a public example through its longevity research investments and a 2023 spinout it financed at the $300,000 level before lining up more dollars for 2024 milestones.

The thesis is to reward verified progress in smaller increments and to create liquid, transparent exposure to research outcomes that many investors can track and govern, rather than waiting years for a grant renewal or a closed-door licensing deal.

Investors get earlier signals, researchers get faster go or no-go decisions, and community stakeholders can influence priorities that were previously locked inside review panels and corporate R&D committees. It is imperfect and still small, but there is a clear demand for faster capital when public cycles tighten and the cost of validation keeps rising.

TradSci: Identify agency calls, write proposals, wait months, and accept low hit rates like 19 percent for 2024 NIH R01 equivalent grants, which select for grant writing stamina as much as scientific novelty in many cases.

DeSci: Use DAOs for faster, milestone-gated grants that can bridge the valley of death and route community capital to narrow problems, as VitaDAO’s 2023 to 2024 activity suggests through a spinout and a portfolio of longevity experiments tracked in public.

2. IP and Ownership

Under TradSci, IP sits within universities, corporate labs, or publisher-controlled agreements that can take months to negotiate and make patient or community participation hard to structure, especially when rights are splintered between institutions and sponsors.

Molecule’s IP-NFT and downstream IP Tokens architecture tries to unify data, IP, and economic rights into a programmable unit, so that labs can raise funds earlier and communities can hold fractional governance over licensing and development paths from day one, with on-chain records that timestamp claims and changes.

That matters because it can make future royalties and milestones legible to more backers, reduce disputes about provenance, and align funders with patient advocates who want to prioritize access over pure profit maximization in later deals.

It is not a silver bullet; however, the shift from PDFs and siloed contracts to composable IP primitives is a tangible change in how ownership and accountability show up in the lab to market journey.

TradSci: IP fragmented across tech transfer offices and private contracts that can leave patients and donors with little visibility or bargaining power, which slows deals and complicates sharing.

DeSci: IP-NFTs unify rights, data, and economics in programmable units, while IP Tokens extend fractional governance so funders and communities can help steer licensing and research directions with clear on-chain records.

3. Publishing and Access

TradSci’s publishing economy still leans on subscriptions, embargoes, and high APCs for gold OA, with Nature’s €9,500 price point a telling benchmark that can exclude unfunded or global south scholars even as hybrid and transformative agreements expand.

DeSci leans into preprints, open repositories, and on-chain attestations that record methods and data early so the community can review, cite, and improve work without waiting for a final typeset version behind a paywall, while tools like Unpaywall help readers legally find accessible copies when available.

The benefit is speed and inclusion for readers and reviewers, and a path toward continuous peer review rather than a one-time gate at acceptance that can bury negative results and valuable null findings. The cost is more noise and the need for better curation, but the direction of travel is toward wider, faster access that complements rather than replaces formal journals for many fields.

TradSci: Prestige journals remain gatekeepers, and OA costs are steep at the top end, like €9,500 for Nature gold OA, which reinforces paywalls and budget constraints despite policy pushes for openness.

DeSci: Preprints, repositories, and OA discovery tools like Unpaywall reduce access friction while on-chain attestations provide provenance for versions and reviews that journals can later integrate with instead of reinventing, speeding knowledge diffusion.

4. Data Integrity and Reproducibility

A Nature survey found more than 70 percent of scientists had tried and failed to reproduce a colleague’s results, which shows how hard it is to capture the full method, data processing, and edge cases inside a standard paper and supplementary PDF.

DeSci proposes that more of the scientific record should be machine-readable, time-stamped, and tamper-evident from the start, whether that is raw data hashes, protocol commits, or milestone proofs that map to funding disbursements and later publications.

If teams link disbursements to transparent on-chain checkpoints, third parties can audit claims more easily, and meta scientists can build better reproducibility tooling that consumes these primitives rather than scraping PDFs and emailing authors for missing files.

This is early, but it directly targets the gaps highlighted in reproducibility surveys and recent biomedical studies that reaffirm the scale of the problem and the cultural issues behind it.

TradSci: Supplementary PDFs and inconsistent data deposit practices make it hard to repeat complex pipelines, as shown by Nature’s survey where more than 70 percent of scientists reported failed replication attempts.

DeSci: Timestamped commits, data hashes, and funding tied to open methods make the default more verifiable, while community bounties can reward independent replication and review where grants often lack room for such work.

5. Governance and Collaboration

TradSci governance runs through PIs, departments, IRBs, grant program officers, and publisher boards, which ensures rigor but can slow cross-domain collaboration or narrow the set of questions that get funded when risk appetite declines.

DeSci shifts some decision rights to token-aligned communities that can back risky ideas, run open calls, and delegate budgets to working groups with defined scopes and SLAs, and projects like VitaDAO have built these processes around specific disease areas like longevity.

Token voting is not magic, yet it creates a public ledger of priorities and tradeoffs that any contributor can audit, and it allows novel participants such as patient groups to gain formal roles beyond advocacy and crowdfunding.

Over time, this can blend with TradSci governance, for instance, by using DAOs as co-funders that plug into university tech transfer or by using IP tokens to formalize community advisory input before a pharma deal closes.

TradSci: Centralized committees and tenure incentives undervalue maintenance, replication, and negative results, and public grant squeezes exacerbate risk aversion when budgets tighten.

DeSci: Token-aligned communities can fund unglamorous but vital work and document it in ways that raise career value, which in turn can attract new contributors like patient advocates and citizen scientists to formal roles in research pipelines.

Key Differences: DeSci vs. TradSci at a Glance

People of Interest or Benefits

Vitalik Buterin framed DeSci as a collection of ideas, asking how open decentralized technologies can make science better, which mirrors the pragmatic ethos of crypto infrastructure after the speculation fades and the tooling becomes boring and useful for narrow problems like timestamping lab notebooks or pooling capital for a neglected protocol. In practice, that means researchers can leverage DAOs to get earlier validation signals, not just money, and then document both failed and successful milestones in a shared ledger that is hard to game for reputation points alone.

For patients, particularly in areas like longevity and rare diseases, the chance to help steer priorities and to hold a sliver of rights in future IP is both symbolic and, potentially, financially meaningful if deals reference on-chain terms instead of opaque side letters that never see the light. For investors, there is a way to back science without waiting for a binary clinical event years out, because tokenized IP and DAO treasuries can mark progress in smaller, verifiable steps that map to a credible funding roadmap rather than a single giant bet.

Kelly Cobey, a metascientist at the University of Ottawa, told Fierce Biotech that updated survey data on reproducibility in biomedicine validated what many anticipated, as 72 percent of more than 1,600 researchers agreed the field faces a reproducibility crisis and many blamed publish or perish incentives and limited funding for replication.

Those incentives are structural, which is why simply adding more checklists will not fix the deeper issue of who gets paid and when, and why negative results still struggle to see daylight in venues that reward novelty over clarity and code sharing.

DeSci will not solve culture overnight, but it can redirect money and status toward better documentation and open methods if treasuries require it as a condition of funding and if IP packaging makes replication a value add rather than a cost center. The hope is that better incentive design, not just better preaching, nudges behavior across labs and publishers that have struggled to scale preregistration, code availability, and data deposit practices beyond the most conscientious teams.

Looking Ahead

Analysts now predict a world where rising global R&D spend continues alongside tightening public grant rates, which creates pressure to diversify how early projects get funded and measured, especially as the United States and China anchor the top tier while others jockey to climb the league tables. In that world, DAOs and IP tokens will likely serve as co-funding rails rather than replacements, not least because regulators, IRBs, and pharma partners still govern downstream trials and markets that require compliance and risk controls that on-chain tools must integrate with step by step.

VitaDAO’s early spinout financing and plans to deepen capitalization into 2024 showed how a community treasury can seed a biotech startup around a specific hypothesis, then invite later-stage capital once the next milestone locks, which hints at a pipeline where DAOs handle hypothesis generation and de-risking before VCs or strategics scale.

If publishing costs at the high end remain at levels like €9,500 for gold OA in elite journals, expect more preprint plus repository first workflows, layered with attestations and reviewer bounties that make open peer review more visible and valuable to committees and hiring panels, even if journals still confer prestige signals for some promotions and grants.

Key Player Spotlight: Vitadao’s Signal

VitaDAO closed a $4 million round in early 2023, headlined by Pfizer Ventures, and has since been involved in funding early-stage longevity projects, including the launch of Matrix Biosciences with an initial $300,000 check and a plan for follow-on funding tied to tokenized IP, which is a template for a DAO-to-spinout motion in DeSci.

The mechanics are straightforward: raise capital into a transparent treasury, source proposals from leading labs such as those studying naked mole rat biology, hold community votes on priorities, and wire funds upon approval, then reflect progress through an IP framework that is designed for transparent licensing later on.

This is not the only path, but it is one that many investors and patient groups can understand since it maps to familiar seed and milestone stages, only with more public audit trails and community participation than a traditional venture lead deal. If the model scales, expect more specialized DAOs around disease areas to emerge and to co-invest with philanthropic and public sources where mandates align, which can also help spread risk across a portfolio rather than betting on any single moonshot.

What Skeptics Get Right

Skeptics point out that token voting can be gamed and that many DeSci efforts rely on small, enthusiastic communities that may not generalize to large clinical programs, which is a fair read of early-stage experiments that need time to mature. They also note that elite publishing and regulatory hurdles still set the rules of the game for credibility and market access, and for now, OA pricing and journal prestige remain powerful signals in hiring and funding.

Even so, the shift toward programmable IP and more transparent funding rails is compatible with these constraints, and early examples like VitaDAO’s spinout show how the models can plug into the existing system rather than try to bulldoze it. If the goal is to reduce waste and speed validation, DeSci only has to make grant writing weeks shorter and method sharing slightly better to compound meaningful gains over a decade.

Closing Thought

If global R&D keeps climbing toward the USD 3 trillion mark and public grant success rates stay tight, will the labs and startups that win the next decade be the ones that master DeSci’s programmable IP and community-governed funding before everyone else catches up?